Covaxin to be evaluated as a COVID-19 vaccine in the US, Say Sources
Bharat Biotech said Covaxin, India’s COVID-19 vaccine, will be evaluated as a vaccine candidate in the United States.
“Covaxin will be evaluated as a Covid-19 vaccine candidate in the United States. The US biotech company Ocugen announced that the US Food and Drug Administration (FDA) has lifted the process. clinical custody of the company’s Investigative New Drug (IND) Application for Evaluation of Covid-19 Vaccine Candidate, BBV152, known as Covaxin outside of the United States, “based vaccine manufacturer” in Hyderabad said in a statement.
‘Covaxin is India’s native Covid-19 vaccine manufactured by Bharat Biotech, developed in partnership with Indian Council of Medical Research (ICMR) – National Institute of Virology (NIV).’
Ocugen is co-developing Bharat Biotech’s Covaxin vaccine candidate for Covid-19 in the US and Canada.
Covaxin is one of two vaccines being used mainly in India.
Covaxin has been granted an Emergency Use List (EUL) in 13 countries to date, according to the World Health Organization.
It was approved for emergency use by the Directorate General of Drugs of India (DCGI) for 12-18 year olds on 24 December 2021.
Source: IANS